NCT06496789View on ClinicalTrials.gov

Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 27, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 31, 2024

Conditions
Gastric Adenocarcinoma
Interventions
DRUG

Serplulimab+SOX

Serplulimab+Oxaliplatin+S1

Trial Locations (1)

Unknown

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER